Citius Oncology opened lower at $0.54, compared with its previous close of $0.55. In the last trading session, the stock traded between $0.52 and $0.57. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Citius Oncology is now worth
$ 16.25
Resulting in a loss of
$ 83.75 (83.75%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.03 (-6.29%)
Day High
$0.57
Day Low
$0.52
Day Open
$0.54
Prev Close
$0.55
Volume
72,708
1W Return
-4.41%
1M Return
-35.00%
3M Return
-27.88%
6M Return
-42.48%
1Y Return
-62.04%
Fundamentals
Market Cap ($ Mn)
48
PE Ratio
-
PB Ratio
2.06
PEG Ratio
-
ROE
-61.80%
ROCE
-51.00%
EPS (TTM)
-
Investment Returns
1 Week
-4.41%
1 Month
-35.00%
3 Months
-27.88%
6 Months
-42.48%
9 Months
-53.98%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
3.9
Dec 25
1.7
Mar 26
1.5
Jun 26
Updates
15Aug
Citius Pharma Q3 EPS beats estimate, sales miss by 72%
Citius Pharma (NASDAQ: CTXR) delivered a mixed third-quarter report, beating EPS estimates with a loss of $(0.34) per share versus $(0.36) expected. However, sales of $1.494 million missed the $5.467 million consensus by 72.67%, indicating significant deviation from projected commercial traction despite improved profitability metrics year-over-year.
3mo ago
5Aug
Citius Oncology sees 78% surge in LYMPHIR institutional orders
Citius Oncology sees a 78% quarter-over-quarter increase in new institutions ordering LYMPHIR, with 42 total institutions now stocking the therapy. Vial orders rose 31%, supported by near-universal payer coverage and a target of 100 priority formulary inclusions by year-end.
3mo ago
21Jul
Citius Oncology expands LYMPHIR launch team nationwide
Citius Oncology expanded its commercial team by adding 29 professionals to support the LYMPHIR launch, facilitated by May 2026 financing and partner EVERSANA. The company reports near 100% payer coverage and utilizes an AI platform to drive growth, targeting a $400 million market.
